-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
August 12, 2022/eMedClub News/--On August 9, 2022, China National Medical Products Administration Center for Drug Evaluation (NMPA) announced that Sichuan Kangdesai Medical Technology Co.
Condésai has received multiple rounds of investment from funds such as BGI, Beijing Enterprises Medical, KIP, Skycom Capital and Tsinghua Tus, with a financing scale of over 100 million yuan
.
In order to better promote the progress of multiple clinical trials, the company is currently seeking a new round of financing
.
Condésai has received multiple rounds of investment from funds such as BGI, Beijing Enterprises Medical, KIP, Skycom Capital and Tsinghua Tus, with a financing scale of over 100 million yuan
.
In order to better promote the progress of multiple clinical trials, the company is currently seeking a new round of financing
.